Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Kai Hübel(University Hospital Cologne), Nicolaus Kröger(Universität Hamburg), Martin Ebinger(University Children's Hospital Tübingen), Wolf Rösler, Frank Heits(Agaplesion Diakonieklinikum Rotenburg), R Hartwig(BG Klinikum Duisburg), Norbert Frickhofen(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Sabine Dressler(Nuremberg Hospital), Michael H. Albert(Ludwig-Maximilians-Universität München), Maximilian Christopeit, Maximilian M. Fresen(University Hospital Cologne), Dominik Wehler(Johannes Gutenberg University Mainz), Sebastian Theurich(University Hospital Cologne), Christian Weigelt(Heinrich Heine University Düsseldorf), Nadežda Basara(Malteser-Krankenhaus), Michael Kiehl(Klinikum Frankfurt Höchst), Florian Lordick(Leipzig University), Bernd Hertenstein(San Antonio College), Oliver Galm(Universitätsklinikum Aachen), Hans Salwender(Asklepios Klinik Altona), Florian Lange(University Hospital Cologne), Simone Liebler(Universitätsklinikum Gießen und Marburg), M von Lilienfeld-Toal(University of Bonn), Eckhart Weidmann(Krankenhaus Nordwest), A R Zander(Universität Hamburg), Christian Bogner(TUM Klinikum), Rita Beier(Medizinische Hochschule Hannover)
Bone Marrow Transplantation
October 25, 2010
10.1038/bmt.2010.249
Cited by 79

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k